Sympathetic nervous dysregulation in the absence of systolic left ventricular dysfunction in a rat model of insulin resistance with hyperglycemia

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Thackeray, James T ^a,c   Radziuk, Jerry ^b   Harper, Mary Ellen ^a,c   Suuronen, Erik J ^a,c   Ascah, Kathryn J ^a   Beanlands, Rob S ^a,c   DaSilva, Jean N ^a,c  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

11C meta hydroxyephedrine (HED); Cardiovascular disease; Diabetes mellitus; norepinephrine; Positron emission tomography; Small animal echocardiography

Indexed keywords

META HYDROXYEPHEDRINE C 11; NORADRENALIN; TRACER; UNCLASSIFIED DRUG; NORADRENALIN TRANSPORTER; STREPTOZOCIN;

ADRENERGIC SYSTEM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; ECHOCARDIOGRAPHY; FLOW RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART RATE; HYPERGLYCEMIA; HYPOINSULINEMIA; IN VIVO STUDY; INSULIN RESISTANCE; MALE; MITRAL VALVE; NONHUMAN; NORADRENALIN BLOOD LEVEL; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; ANIMAL; CHEMICALLY INDUCED DISORDER; DIASTOLE; DISEASE MODEL; ECHOGRAPHY; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SCINTISCANNING; SPRAGUE DAWLEY RAT; SYSTOLE;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIASTOLE; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; HYPERGLYCEMIA; INSULIN RESISTANCE; MALE; MYOCARDIUM; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN; SYMPATHETIC NERVOUS SYSTEM; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 81155158871     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-75     Document Type: Article

References (51)

1. Kostis JB, Sanders M. The association of heart failure with insulin resistance and the development of type 2 diabetes. Am J Hypertens 2005, 18(5 Pt 1):731-737.
2. Sharma V, Dhillon P, Wambolt R, Parsons H, Brownsey R, Allard MF, McNeill JH. Metoprolol improves cardiac function and modulates cardiac metabolism in the streptozotocin-diabetic rat. Am J Physiol Heart Circ Physiol 2008, 294(4):H1609-1620. 10.1152/ajpheart.00949.2007, 18203848.
3. van den Brom CE, Huisman MC, Vlasblom R, Boontje NM, Duijst S, Lubberink M, Molthoff CF, Lammertsma AA, van der Velden J, Boer C, et al. Altered myocardial substrate metabolism is associated with myocardial dysfunction in early diabetic cardiomyopathy in rats: studies using positron emission tomography. Cardiovasc Diabetol 2009, 8:39. 10.1186/1475-2840-8-39, 2722582, 19624828.
4. Connelly KA, Kelly DJ, Zhang Y, Prior DL, Martin J, Cox AJ, Thai K, Feneley MP, Tsoporis J, White KE, et al. Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc Res 2007, 76(2):280-291. 10.1016/j.cardiores.2007.06.022, 17716638.
5. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation 2002, 105(14):1727-1733. 10.1161/01.CIR.0000012466.50373.E8, 11940554.
6. Dincer UD, Bidasee KR, Guner S, Tay A, Ozcelikay AT, Altan VM. The effect of diabetes on expression of beta1-, beta2-, and beta3-adrenoreceptors in rat hearts. Diabetes 2001, 50(2):455-461. 10.2337/diabetes.50.2.455, 11272160.
7. Stevens MJ, Raffel DM, Allman KC, Schwaiger M, Wieland DM. Regression and progression of cardiac sympathetic dysinnervation complicating diabetes: an assessment by C-11 hydroxyephedrine and positron emission tomography. Metabolism 1999, 48(1):92-101. 10.1016/S0026-0495(99)90016-1, 9920151.
8. Kusmic C, Morbelli S, Marini C, Matteucci M, Cappellini C, Pomposelli E, Marzullo P, L'Abbate A, Sambuceti G. Whole-body evaluation of MIBG tissue extraction in a mouse model of long-lasting type II diabetes and its relationship with norepinephrine transport protein concentration. J Nucl Med 2008, 49(10):1701-1706. 10.2967/jnumed.108.054361, 18794257.
9. Lameris TW, de Zeeuw S, Alberts G, Boomsma F, Duncker DJ, Verdouw PD, Veld AJ, van Den Meiracker AH. Time course and mechanism of myocardial catecholamine release during transient ischemia in vivo. Circulation 2000, 101(22):2645-2650.
10. Raffel DM, Wieland DM. Assessment of cardiac sympathetic nerve integrity with positron emission tomography. Nucl Med Biol 2001, 28(5):541-559. 10.1016/S0969-8051(01)00210-4, 11516699.
11. Ungerer M, Hartmann F, Karoglan M, Chlistalla A, Ziegler S, Richardt G, Overbeck M, Meisner H, Schomig A, Schwaiger M. Regional in vivo and in vitro characterization of autonomic innervation in cardiomyopathic human heart. Circulation 1998, 97(2):174-180.
12. Li W, Knowlton D, Van Winkle DM, Habecker BA. Infarction alters both the distribution and noradrenergic properties of cardiac sympathetic neurons. Am J Physiol Heart Circ Physiol 2004, 286(6):H2229-2236. 10.1152/ajpheart.00768.2003, 14726300.
13. Schmid H, Forman LA, Cao X, Sherman PS, Stevens MJ. Heterogeneous cardiac sympathetic denervation and decreased myocardial nerve growth factor in streptozotocin-induced diabetic rats: implications for cardiac sympathetic dysinnervation complicating diabetes. Diabetes 1999, 48(3):603-608. 10.2337/diabetes.48.3.603, 10078563.
14. Levin BE, Sullivan AC. Glucose-induced norepinephrine levels and obesity resistance. Am J Physiol 1987, 253(3 Pt 2):R475-481.
15. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991, 87(6):2246-2252. 10.1172/JCI115260, 296986, 2040704.
16. Ganguly PK, Beamish RE, Dhalla KS, Innes IR, Dhalla NS. Norepinephrine storage, distribution, and release in diabetic cardiomyopathy. Am J Physiol 1987, 252(6 Pt 1):E734-739.
17. Howarth FC, Jacobson M, Shafiullah M, Adeghate E. Long-term effects of streptozotocin-induced diabetes on the electrocardiogram, physical activity and body temperature in rats. Exp Physiol 2005, 90(6):827-835. 10.1113/expphysiol.2005.031252, 16091403.
18. Marsh SA, Powell PC, Agarwal A, Dell'Italia LJ, Chatham JC. Cardiovascular dysfunction in Zucker obese and Zucker diabetic fatty rats: role of hydronephrosis. Am J Physiol Heart Circ Physiol 2007, 293(1):H292-298. 10.1152/ajpheart.01362.2006, 17351065.
19. Marsh SA, Dell'italia LJ, Chatham JC. Interaction of diet and diabetes on cardiovascular function in rats. Am J Physiol Heart Circ Physiol 2009, 296(2):H282-292. 2643886, 19036853.
20. Dias LD, Casali KR, Leguisamo NM, Azambuja F, Souza MS, Okamoto M, Machado UF, Irigoyen MC, Schaan BD. Renal denervation in an animal model of diabetes and hypertension: Impact on the autonomic nervous system and nephropathy. Cardiovasc Diabetol 2011, 10:33. 10.1186/1475-2840-10-33, 3110548, 21496329.
21. Rodrigues B, Rosa KT, Medeiros A, Schaan BD, Brum PC, De Angelis K, Irigoyen MC. Hyperglycemia can delay left ventricular dysfunction but not autonomic damage after myocardial infarction in rodents. Cardiovasc Diabetol 2011, 10:26. 10.1186/1475-2840-10-26, 3084163, 21470409.
22. Raffel DM, Chen W, Sherman PS, Gildersleeve DL, Jung YW. Dependence of cardiac 11C-meta-hydroxyephedrine retention on norepinephrine transporter density. J Nucl Med 2006, 47(9):1490-1496. 1618973, 16954558.
23. Thackeray JT, Beanlands RS, Dasilva JN. Presence of Specific 11C-meta-Hydroxyephedrine Retention in Heart, Lung, Pancreas, and Brown Adipose Tissue. J Nucl Med 2007, 48(10):1733-1740. 10.2967/jnumed.107.043570, 17873125.
24. Zhang F, Ye C, Li G, Ding W, Zhou W, Zhu H, Chen G, Luo T, Guang M, Liu Y, et al. The rat model of type 2 diabetic mellitus and its glycometabolism characters. Exp Anim 2003, 52(5):401-407. 10.1538/expanim.52.401, 14625406.
25. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, Gadbois TM, Reaven GM. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 2000, 49(11):1390-1394. 10.1053/meta.2000.17721, 11092499.
26. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 2005, 52(4):313-320. 10.1016/j.phrs.2005.05.004, 15979893.
27. Wang Y, Fice DS, Yeung PK. A simple high-performance liquid chromatography assay for simultaneous determination of plasma norepinephrine, epinephrine, dopamine and 3,4-dihydroxyphenyl acetic acid. J Pharm Biomed Anal 1999, 21(3):519-525. 10.1016/S0731-7085(99)00117-X, 10701418.
28. Greene M, Thackeray JT, Kenk M, Thorn SL, Bevilacqua L, Harper M-E, Beanlands RS, DaSilva JN. Reduced In Vivo Phosphodiesterase-4 Response to Norepinephrine Challenge in Diet-Induced Obese Rats. Can J Physiol Pharmacol 2009, 87:196-202. 10.1139/Y09-001, 19295660.
29. Wehrwein EA, Parker LM, Wright AA, Spitsbergen JM, Novotny M, Babankova D, Swain GM, Habecker BA, Kreulen DL. Cardiac norepinephrine transporter protein expression is inversely correlated to chamber norepinephrine content. Am J Physiol Regul Integr Comp Physiol 2008, 295(3):R857-863. 10.1152/ajpregu.00190.2008, 2536859, 18565836.
30. Cao JM, Fishbein MC, Han JB, Lai WW, Lai AC, Wu TJ, Czer L, Wolf PL, Denton TA, Shintaku IP, et al. Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. Circulation 2000, 101(16):1960-1969.
31. Enomoto H, Crawford PA, Gorodinsky A, Heuckeroth RO, Johnson EM, Milbrandt J. RET signaling is essential for migration, axonal growth and axon guidance of developing sympathetic neurons. Development 2001, 128(20):3963-3974.
32. Ieda M, Kanazawa H, Ieda Y, Kimura K, Matsumura K, Tomita Y, Yagi T, Onizuka T, Shimoji K, Ogawa S, et al. Nerve growth factor is critical for cardiac sensory innervation and rescues neuropathy in diabetic hearts. Circulation 2006, 114(22):2351-2363. 10.1161/CIRCULATIONAHA.106.627588, 17101855.
33. Houwing H, Benthem L, Van Suylichem PT, Van der Leest J, Strubbe JH, Steffens AB. Islet transplantation in diabetic rats normalizes basal and exercise-induced energy metabolism. Diabetologia 1995, 38(8):919-926. 10.1007/BF00400580, 7589877.
34. Meex RC, Schrauwen-Hinderling VB, Moonen-Kornips E, Schaart G, Mensink M, Phielix E, van de Weijer T, Sels JP, Schrauwen P, Hesselink MK. Restoration of muscle mitochondrial function and metabolic flexibility in type 2 diabetes by exercise training is paralleled by increased myocellular fat storage and improved insulin sensitivity. Diabetes 59(3):572-579.
35. Kim SK, Zhao ZS, Lee YJ, Lee KE, Kang SM, Choi D, Lim SK, Chung N, Lee HC, Cha BS. Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model. Diabetes Metab Res Rev 2003, 19(6):487-493. 10.1002/dmrr.410, 14648808.
36. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol 2010, 55(4):300-305. 10.1016/j.jacc.2009.12.003, 20117433.
37. Kiyono Y, Iida Y, Kawashima H, Ogawa M, Tamaki N, Nishimura H, Saji H. Norepinephrine transporter density as a causative factor in alterations in MIBG myocardial uptake in NIDDM model rats. Eur J Nucl Med Mol Imaging 2002, 29(8):999-1005. 10.1007/s00259-002-0798-1, 12173012.
38. Kiyono Y, Iida Y, Kawashima H, Tamaki N, Nishimura H, Saji H. Regional alterations of myocardial norepinephrine transporter density in streptozotocin-induced diabetic rats: implications for heterogeneous cardiac accumulation of MIBG in diabetes. Eur J Nucl Med 2001, 28(7):894-899. 10.1007/s002590100550, 11504086.
39. Mardon K, Montagne O, Elbaz N, Malek Z, Syrota A, Dubois-Rande JL, Meignan M, Merlet P. Uptake-1 carrier downregulates in parallel with the beta-adrenergic receptor desensitization in rat hearts chronically exposed to high levels of circulating norepinephrine: implications for cardiac neuroimaging in human cardiomyopathies. J Nucl Med 2003, 44(9):1459-1466.
40. Thackeray JT, Parsa-Nezhad M, Kenk M, Thorn SL, Kolajova M, Beanlands RS, DaSilva JN. Reduced CGP12177 binding to cardiac beta-adrenoceptors in hgyperglycemic high-fat-diet-fed, streptozotocin-induced diabetic rats. Nucl Med Biol 2011,
41. Raimondi L, De Paoli P, Mannucci E, Lonardo G, Sartiani L, Banchelli G, Pirisino R, Mugelli A, Cerbai E. Restoration of cardiomyocyte functional properties by angiotensin II receptor blockade in diabetic rats. Diabetes 2004, 53(7):1927-1933. 10.2337/diabetes.53.7.1927, 15220222.
42. Mongillo M, John AS, Leccisotti L, Pennell DJ, Camici PG. Myocardial pre-synaptic sympathetic function correlates with glucose uptake in the failing human heart. Eur J Nucl Med Mol Imaging 2007, 34(8):1172-1177. 10.1007/s00259-007-0371-z, 17294189.
43. Nakajima-Takenaka C, Zhang GX, Obata K, Tohne K, Matsuyoshi H, Nagai Y, Nishiyama A, Takaki M. Left ventricular function of isoproterenol-induced hypertrophied rat hearts perfused with blood: mechanical work and energetics. Am J Physiol Heart Circ Physiol 2009, 297(5):H1736-1743. 10.1152/ajpheart.00672.2009, 19734357.
44. Keller NR, Diedrich A, Appalsamy M, Tuntrakool S, Lonce S, Finney C, Caron MG, Robertson D. Norepinephrine transporter-deficient mice exhibit excessive tachycardia and elevated blood pressure with wakefulness and activity. Circulation 2004, 110(10):1191-1196. 10.1161/01.CIR.0000141804.90845.E6, 15337696.
45. Munch G, Rosport K, Bultmann A, Baumgartner C, Li Z, Laacke L, Ungerer M. Cardiac overexpression of the norepinephrine transporter uptake-1 results in marked improvement of heart failure. Circ Res 2005, 97(9):928-936. 10.1161/01.RES.0000186685.46829.E5, 16166553.
46. Henriksen EJ. Improvement of Insulin Sensitivity by Antagonism of the Renin-Angiotensin System. Am J Physiol Regul Integr Comp Physiol 2007,
47. Maiese K, Chong ZZ, Shang YC. Mechanistic insights into diabetes mellitus and oxidative stress. Curr Med Chem 2007, 14(16):1729-1738. 2447161, 17627510.
48. Rupp H, Dhalla KS, Dhalla NS. Mechanisms of cardiac cell damage due to catecholamines: significance of drugs regulating central sympathetic outflow. J Cardiovasc Pharmacol 1994, 24(Suppl 1):S16-24.
49. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, Agostini D, Weiland F, Chandna H, Narula J. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010, 55(20):2212-2221. 10.1016/j.jacc.2010.01.014, 20188504.
50. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009, 301(15):1547-1555. 10.1001/jama.2009.476, 2895332, 19366774.
51. Diggs-Andrews KA, Zhang X, Song Z, Daphna-Iken D, Routh VH, Fisher SJ. Brain insulin action regulates hypothalamic glucose sensing and the counterregulatory response to hypoglycemia. Diabetes 2010, 59(9):2271-2280. 10.2337/db10-0401, 20547974.